FOXO4-DRI Peptide Vial

Product Overview

FOXO4-DRI is a D-amino acid retro-inverso peptide engineered to interfere with the interaction between the FOXO4 transcription factor and the p53 protein within senescent cells. Senescent cells — sometimes referred to in scientific literature as ‘zombie cells’ — are metabolically active but non-dividing cells that accumulate in tissues over time and are associated with chronic inflammation and age-related tissue dysfunction. The FOXO4-DRI Peptide Vial available at Direct Anti Peptide is produced to ≥98% purity and is intended exclusively for in vitro and preclinical research settings. Researchers investigating cellular senescence, tissue homeostasis, and longevity biology will find this compound to be a valuable addition to their experimental toolkit.

Peptide Structure & Amino Acid Sequence

FOXO4-DRI is a retro-inverso peptide, meaning it is constructed from D-amino acids arranged in a reversed sequence relative to the native L-amino acid parent peptide. This structural modification confers significant proteolytic resistance compared to conventional L-peptides, making FOXO4-DRI particularly stable under physiological buffer conditions used in cell culture and biochemical assay environments. The retro-inverso architecture allows the peptide to mimic the spatial orientation of its native counterpart while resisting enzymatic degradation — a critical advantage for researchers requiring extended stability in experimental media. The specific sequence targets the FOXO4–p53 protein–protein interaction interface, a mechanistic feature that makes this peptide of considerable interest in senolytic and geroscience research programs.

Chemical & Physical Characteristics

• Peptide Type: D-amino acid retro-inverso peptide
• Appearance: White to off-white lyophilized powder
• Purity: ≥98% (HPLC verified)
• Solubility: Soluble in aqueous buffers; consult peer-reviewed literature for optimal reconstitution conditions for your specific assay
• Molecular Target: FOXO4–p53 protein interaction interface
• Storage Form: Lyophilized (freeze-dried) powder in sterile glass vial
• Stability: Enhanced proteolytic resistance due to D-amino acid configuration

Purity & Analytical Verification (HPLC & MS)

Every batch of FOXO4-DRI Peptide Vial supplied by Direct Anti Peptide undergoes rigorous analytical quality control prior to release. High-performance liquid chromatography (HPLC) is used to confirm a purity level of ≥98%, ensuring that researchers receive a compound with minimal impurities that could confound experimental results. Mass spectrometry (MS) analysis is performed to verify the correct molecular weight and confirm peptide identity, providing an additional layer of analytical confidence. Certificates of Analysis (CoA) reflecting these results are available upon request and are an integral part of our quality assurance commitment to the research community.

Quality Control & Lyophilization Integrity

The lyophilization process used in the preparation of each FOXO4-DRI Peptide Vial is conducted under controlled conditions designed to preserve structural integrity, biological activity potential, and long-term stability. Lyophilized peptides are inherently more stable than peptides in solution, offering extended shelf life when stored under appropriate conditions. Each vial is sealed under inert atmosphere and inspected for visual clarity, fill integrity, and stopper security before dispatch. Direct Anti Peptide’s quality control protocols are designed to meet the expectations of professional research institutions requiring consistent, reproducible compound performance across experimental replicates.

Safety, Handling & Laboratory Precautions

This compound is supplied strictly for research use by trained laboratory professionals operating within appropriately equipped facilities. Standard laboratory personal protective equipment (PPE) — including gloves, lab coat, and eye protection — should be worn when handling lyophilized peptide material. The compound should be handled in accordance with your institution’s chemical hygiene plan and applicable biosafety protocols. This product is not approved for administration to humans or animals under any circumstances. Researchers should consult applicable institutional review and ethics guidelines before initiating any experimental program involving this compound.

Reconstitution, Packaging & Storage

The FOXO4-DRI Peptide Vial is supplied as a lyophilized powder housed in a sterile borosilicate glass vial, which provides superior protection against moisture ingress, oxidative degradation, and UV light exposure. Researchers should consult peer-reviewed literature and established laboratory protocols to determine the most appropriate reconstitution solvent, concentration, and buffer conditions for their specific assay requirements. Upon reconstitution, aliquoting is recommended to minimize freeze-thaw cycling. Lyophilized stock should be stored at −20°C or below, protected from light and humidity. Reconstituted solutions should be used promptly or stored according to validated in-house stability data.

Intended Research Use & Market Positioning

FOXO4-DRI is of significant interest to researchers working in the fields of cellular senescence, geroscience, longevity biology, and preclinical aging model development. Its mechanism of action — disrupting the FOXO4–p53 interaction to promote apoptosis of senescent cells — positions it as a tool compound in senolytic research programs. Direct Anti Peptide offers this compound for sale online to qualified research buyers seeking a reliable, high-purity source of FOXO4-DRI for laboratory investigation. This peptide is not positioned as a therapeutic agent and has not received regulatory approval for clinical use in any jurisdiction.

Ordering, Availability & Fulfillment

Researchers looking to buy FOXO4-DRI Peptide Vial online can order now directly through Direct Anti Peptide’s secure eCommerce platform. We offer competitive best-price positioning, efficient order processing, and reliable international fulfillment to support research institutions, universities, and private laboratories worldwide. All orders are dispatched with full documentation including batch-specific CoA. For bulk orders or institutional procurement inquiries, please contact our research support team directly.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. FOXO4-DRI Peptide Vial is sold exclusively as a laboratory research reagent. It has not been evaluated by any regulatory authority for safety or efficacy in humans or animals. Direct Anti Peptide assumes no liability for misuse, improper handling, or use outside of a controlled research environment. All purchasers are solely responsible for ensuring compliance with applicable local, national, and international laws and regulations governing the procurement, possession, and use of research peptides. This product must not be used as a drug, food supplement, cosmetic ingredient, or in any application involving human or animal subjects.